Rectal Cancer Consortium

NCT01835925 | Completed DMC

• 1 other identifier: 285
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to study which genes are abnormal in rectal cancer and see if this predicts how well chemotherapy and radiation will reduce the size of cancer and whether cancer recurs after surgery.

Conditions

Rectal Cancer

Keywords

adenocarcinoma of rectum; rectal cancer; stage II; stage III

Outcome Measures

Primary Outcomes (1)

• Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.

  baseline

Secondary Outcomes (1)

• Tumor tissue results with clinical outcome post standard treatment. .

  annually for 5 years

Study Arms (1)

Tissue specmien

Genetic: Tissue specimen

Interventions

Tissue specimen GENETIC

Tissue specmien

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with stage II or III rectal cancer (adenocarcinoma)

You may qualify if:

• Patients must have histologically proven adenocarcinoma of the rectum with no evidence of distant metastases.
• The tumor must be clinically Stage II (T3-4 N0) or III (T1-4 N1-2).
• Patients must have no evidence of distant metastases including liver metastases, peritoneal seeding, or inguinal lymphadenopathy.
• Patients who completed or are actively enrolled in the CONTRE study and patients undergoing treatment for rectal cancer following the TNT (Total Neoadjuvant Treatment) format (see below) for whom sufficient tissue is available for the required research analyses may be enrolled in this study retroactively.
• For those who have not yet received treatment for rectal adenocarcinoma, these patients must not have received prior chemotherapy or pelvic radiation for rectal cancer, or prior pelvic radiation for any other malignancy that would prevent the patient from receiving the required radiation treatments for this study.
• Patients must not have an active concurrent invasive malignancy other than non-melanoma skin cancers. Patients with malignancies diagnosed within 5 years prior to randomization which have been effectively treated and are deemed to be at low risk for recurrence are eligible.
• Patients must be \> 18 years of age, ECOG (performance status) 0-1.
• ANC (absolute neutrophil count) \>1,500/µl, platelets \>100,000/µl, total bilirubin \<2.0 mg/dl or direct bilirubin \<1.0 mg/dl, alkaline phosphatase \<3xULN, ALT \<3xULN, creatinine \<1.5xULN.
• Signed informed consent; able to comply with study and/or follow- up procedures
• Peripheral neuropathy \< grade 1.
• The intention of the treating physicians is to administer Total Neoadjuvant Treatment as per the suggested treatment guidelines in section 4 and section 5 or as per standard institutional policies.

You may not qualify if:

• Evidence of metastatic disease.
• Rectal cancers other than adenocarcinoma, i.e., sarcoma, lymphoma, carcinoid, squamous cell carcinoma, cloacogenic carcinoma, etc.
• Pregnancy or lactation at the time of proposed randomization. Eligible patients of reproductive potential (both sexes) must agree to use adequate contraception.
• Synchronous invasive colon cancer.
• Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude the patient from receiving any chemotherapy treatment option or would prevent required follow-up.
• Patients with active inflammatory bowel disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0 or other serious medical illness which might limit the ability of the patient to receive protocol therapy.
• Known hypersensitivity to 5-fluorouracil or oxaliplatin
• Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
• Insufficient tumor tissue available for the required genomic analyses and patient unable or unwilling to undergo repeat examination and biopsies.

Sponsors & Collaborators

• Brown University: lead

Study Sites (2)

Rhode Island Hospital

Providence, Rhode Island, 02903, United States

Location

The Miriam Hospital

Providence, Rhode Island, 02903, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Tissue specimen from diagnosis from rectal cancer

MeSH Terms

Conditions

Rectal Neoplasms

Interventions

Histocompatibility Testing

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Immunologic Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Immunologic Techniques

Study Officials

• Howard Safran, MD

  Brown University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 9, 2013
• First Posted: April 19, 2013
• Study Start: July 1, 2013
• Primary Completion: April 1, 2014
• Study Completion: April 1, 2014
• Last Updated: May 1, 2014

Record last verified: 2014-04

Locations

US (2)